Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II open label study that will evaluate children ≥ 1 year of age and adults
with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK
inhibitor, binimetinib. The primary objective is to determine if there is an adequate level
of disease responsiveness to binimetinib in children and adults with NF1 and inoperable
plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease
in tumor volume reduction by 12 courses.